Evidence map›Paper›PMID 37717549›Full record

ArticleOral oncology2023

Assessing the capacity of methylated DNA markers of cervical squamous cell carcinoma to discriminate oropharyngeal squamous cell carcinoma in human papillomavirus mediated disease.

Kathleen R Bartemes, Benjamin R Gochanour, David M Routman, Daniel J Ma, Karen A Doering, Kelli N Burger, Patrick H Foote, William R Taylor, Douglas W Mahoney, Calise K Berger and 10 more

Open access · greenAbstract read
In one paragraph

Article in Oral oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 1 country.

Kathleen R BartemesDepartment of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, MN, USA.
Benjamin R GochanourDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
David M RoutmanDepartment of Radiation Oncology, Rochester, MN, USA.
Daniel J MaDepartment of Radiation Oncology, Rochester, MN, USA.
Karen A DoeringDepartment of Gastroenterology, Rochester, MN, USA.
Kelli N BurgerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Patrick H FooteDepartment of Gastroenterology, Rochester, MN, USA.
William R TaylorDepartment of Gastroenterology, Rochester, MN, USA.
Douglas W MahoneyDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
Calise K BergerDepartment of Gastroenterology, Rochester, MN, USA.
Xiaoming CaoDepartment of Gastroenterology, Rochester, MN, USA.
Sara S ThenDepartment of Gastroenterology, Rochester, MN, USA.
Travis J HallerDepartment of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, MN, USA.
Alyssa M LarishDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
Eric J MooreDepartment of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, MN, USA.
Joaquin J GarciaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Rondell P GrahamDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
Jamie N Bakkum-GamezDepartment of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA.
John B KisielDepartment of Gastroenterology, Rochester, MN, USA.
Kathryn M Van AbelDepartment of Otolaryngology, Head and Neck Surgery, Mayo Clinic, Rochester, MN, USA. Electronic address: vanabel.kathryn@mayo.edu.
Mayo Clinic in Arizona · USUniversity of Minnesota Rochester · USMayo Clinic in Florida · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Lila J. Rutten · 1985 to 2026
$151.3M
Multi-site Gastrointestinal Cancer Detection by Stool DNA MethylationR37CA214679 · NCI · MAYO CLINIC ROCHESTER · PI KISIEL, JOHN · 2018 to 2024
$2.8M
Multi-cancer Early DetectionR01CA214679 · NCI · MAYO CLINIC ROCHESTER · PI John Kisiel, Niloy Jewel Samadder · 2025 to 2026
$891k
NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA214679NCI NIH HHS R37 CA214679
6 · The paper itself

Abstract

objectiveEarly identification of human papillomavirus associated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC) is challenging and novel biomarkers are needed. We hypothesized that a panel of methylated DNA markers (MDMs) found in HPV(+) cervical squamous cell carcinoma (CSCC) will have similar discrimination in HPV(+)OPSCC tissues. MATERIALS AND

methodsFormalin-fixed, paraffin-embedded tissues were obtained from patients with primary HPV(+)OPSCC or HPV(+)CSCC; control tissues included normal oropharynx palatine tonsil (NOP) and cervix (NCS). Using a methylation-specific polymerase chain reaction, 21 previously validated cervical MDMs were evaluated on tissue-extracted DNA. Discrimination between case and control cervical and oropharynx tissue was assessed using area under the curve (AUC).

results34 HPV(+)OPSCC, 36 HPV(+)CSCC, 26 NOP, and 24 NCS patients met inclusion criteria. Within HPV(+)CSCC, 18/21 (86%) of MDMs achieved an AUC ≥ 0.9 and all MDMs exhibited better than chance classifications relative to control cervical tissue (all p < 0.001). In contrast, within HPV(+)OPSCC only 5/21 (24%) MDMs achieved an AUC ≥ 0.90 but 19/21 (90%) exhibited better than chance classifications relative to control tonsil tissue (all p < 0.001). Overall, 13/21 MDMs had statistically significant lower AUCs in the oropharyngeal cohort compared to the cervical cohort, and only 1 MDM exhibited a statistically significant increase in AUC.

conclusionsPreviously validated MDMs exhibited robust performance in independent HPV(+)CSCC patients. However, most of these MDMs exhibited higher discrimination for HPV(+)CSCC than for HPV(+)OPSCC. This suggests that each SCC subtype requires a unique set of MDMs for optimal discrimination. Future studies are necessary to establish an MDM panel for HPV(+)OPSCC.

Indexed as

Carcinoma, Squamous CellHead and Neck NeoplasmsOropharyngeal NeoplasmsPapillomavirus InfectionsUterine Cervical NeoplasmsDNA MethylationFemaleGenetic MarkersHuman Papillomavirus VirusesHumansPapillomaviridaeSquamous Cell Carcinoma of Head and NeckGenetic MarkersBiomarkersDNA methylationHuman papillomavirus virusesOropharyngeal cancerUterine cervical neoplasms

Identifiers

PMID37717549
PMCPMC10591712
OpenAlexW4386798667

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.